FDA advances two more Herceptin biosims—this time from Amgen and Teva—as Roche braces for impact
admin 31st July 2017 Uncategorised 0Herceptin biosimilars are coming for Roche in the U.S., and Monday, a pair of them got one big step closer. Amgen-Allergan and Teva-Celltrion duos each said that regulators had accepted regulatory filings for their respective candidates, and Amgen R&D chief Sean Harper dubbed the event “an exciting milestone.”
More: FDA advances two more Herceptin biosims—this time from Amgen and Teva—as Roche braces for impact
Source: fierce